Kornimate/medical-research-clean huggingface dataset:
effect of zanthoxylum nitidum tincture for paronychia caused by afatinib

Conditions: Paronychia

Summary: this is a randomized control trial evaluating the efficacy of zanthoxylum nitidum tincture on preventing progression of paronychia caused by afatinib from grade 1 to grade 2/3. enrolled participates will randomly receive original treatment or original treatment plus zanthoxylum nitidum tincture immersion of the sick nail(s).


Eligibility criteria:
inclusion criteria: 1. pathologically or cytologically confirmed non-small cell lung cancer； 2. undergoing treatment with afatinib； 3. with grade 1 paronychia； 4. age between 18 to 80 years old； 5. estimated life expectancy of more than months； 6. with the written informed consent. exclusion criteria: 1. paronychia before afatinib treatment; 2. grade 2 or severer paronychia; 3. stop using afatinib or with reduced dose of afatinib; 4. currently diagnosed with severe encephalopathy or psychiatric disorders affecting patients ability of self expression. 5. has other legal, medical or ethical reasons that patients are not appropriate for clinical study.

Keywords: paronychia zanthoxylum nitidum tincture afatinib
a retrospective, real-world study of elp used in the expectorant treatment of community-acquired pneumonia

Conditions: Community-acquired Pneumonia

Summary: through a series of retrospective analysis, it is hoped that an objective evaluation of the effect and safety of eucalyptol, limonene and pinene enteric soft capsules in the treatment of community-acquired pneumonia can be made.


Eligibility criteria:
inclusion criteria: 1. patients with community-acquired pneumonia 2. inpatients from 2017 to 2019 3. regardless of age and gender exclusion criteria: 1. patients diagnosed with hospital-acquired pneumonia 2. patients who take two or more oral mucolytics 3. patients with combined use of chinese and western expectorants other than mucolytic drugs
ultrasound guided erector spinae plane block

Conditions: Breast Diseases

Summary: patients were randomized into two groups, esp and control. single-shot ultrasound (us)-guided esp block with 20 ml 0.25% bupivacaine at the t4 vertebral level was performed preoperatively to all patients in the esp group. the control group received no intervention. patients in both groups were provided with intravenous patient-controlled analgesia device containing morphine for postoperative analgesia.


Eligibility criteria:
inclusion criteria: 1. 18-65 age 2. patients who scheduled for bilateral reduction mammoplasty 3. asa class i-ii exclusion criteria: 1. coagulopaty
"using dilute vinegar to find changes in cells during endoscopy for patients with barrett's oesophagus" (the abba study)

Conditions: Barrett Esophagus

Summary: problem statement barrett's oesophagus is a pre-cancerous condition affecting 375,000 people in the u.k. there is a 0.5-3% yearly risk of progressing to oesophageal cancer, from which only 5% of patients will survive for 5 years after diagnosis. diagnosing the disease at the stage of dysplasia (pre-cancerous) and early cancer improves survival. this has led to the current surveillance strategy of gastroscopy with non-targeted mapping biopsies taken from the barrett's oesophagus every two years. the large number of biopsies required is time consuming and expensive, yet dysplasia and cancerous tissue is still missed due to the non-targeted biopsy sampling strategy. acetic acid has been used effectively in the early detection of cervical dysplasia and cancer, and has also been used with success in a high risk barrett's population (patients with suspected dysplasia or previously treated dysplasia), but not been studied in the lower risk barrett's surveillance population. a diagnostic study of non-targeted mapping biopsies (current practice) versus targeted biopsies (acetic acid) in a surveillance population is needed before widespread adoption of this technique is possible.

this is a feasibility study to enable powering of a larger study. the investigators would assume a disease detection of 4.5% with acetic acid chromoendoscopy and 1.5% with protocol driven mapping biopsies. however, these assumptions are largely driven from a single centre cohort study and as such need clarification before they could be used for the purposes of powering a study. based on the historical cohort studies and wide consultation within the british society of gastroenterology research committee and consultation with experts in the field, it is estimated that 200 patients would be reasonable for recruitment to enable the reproducibility and generalisability of this data to be established. the purpose of this study is not to produce statistically significant data in itself but to establish likely event rates and effect size to inform the power calculation for the definitive study.

Eligibility criteria:
inclusion criteria: 1. aged 18 years or above 2. biopsy proven barrett's metaplasia 3. at least 2cm of barrett's metaplasia (c0 m2) 4. willing and able to give informed consent exclusion criteria: 1. less than 2cm (c0 m2) of barrett's metaplasia 2. significant oesophagitis 3. known or prior oesophageal cancer 4. known or prior oesophageal dysplasia (indefinite for dysplasia can be included) 5. previous endoscopic therapy 6. known allergy to acetic acid 7. previous inclusion in the study
biomarker and imaging package study in immune effector cell-associated neurotoxicity syndrome

Conditions: Immune Effector Cell Associated Neurotoxicity Syndrome

Summary: car t-cell therapy is a promising innovative therapy for hematological malignancies. immune effectors cells-associated neurotoxicity syndrome (icans) is a significant complication of car therapy. the goal of this study is to understand what brain mechanisms become disrupted when patients experience icans. the study will test the hypothesis that cerebrospinal fluid catecholamines and multimodal magnetic resonance imaging are affected in this disorder. to test this hypothesis, the study will measure cerebrospinal fluid catecholamines in icans patients and evaluate brain magnetic resonance imaging for these participants. this study may contribute to knowledge about brain biomarkers and imaging of icans, which will greatly aid in icans detection and prevention.


Eligibility criteria:
inclusion criteria: * subjects must be ≥ 18 years of age at signing of informed consent. * subjects are scheduled to receive car t-cell treatment. exclusion criteria: * refusal to sign the informed consent * subjects having previously been treated with car-t therapy. * subjects with clinically significant active bleeding, history of intracranial bleeding, or is at risk for intracranial bleeding * subjects presenting primary cns lymphoma * pacemaker or other implanted electrical device incompatible with the mr environment * subjects with a neurodegenerative disease (pd, ad) * subjects with a previous or evolving neurological pathology * pregnant or breastfeeding women
teledi@log - tele-rehabilitation of heart patients

Conditions: Heart Failure; Myocardial Infarction; Angina Pectoris; Coronary Stenosis; Mitral Valve Stenosis

Summary: the idea behind the teledi@log consortium is to develop tele-rehabilitation concepts and technologies so that all types of heart disease patients, regardless of degree of severity, can be offered individual, customized and coordinated tele-rehabilitation across sectors. the project is innovative, breaking new ground in relation to existing national and international research projects in the area. the teledi@log consortium sees its major task as developing and testing scenarios which can lead to a more coherent rehabilitation for heart patients in areas such as patient training, organization across the boundaries of the health system and using tele-rehabilitation technology. the teledi@log consortium seeks to develop new tele-rehabilitation concepts which bring the patient closer to the health system and thereby promote the heart patient's rehabilitation, giving the patient and their families a more active role via new tele-rehabilitation technologies.the hypothesis of the study is that heart patients participating in a telerehabilitation program will have a higher quality of life compared to heart patients following traditional rehabilitation activities.

the aims of the research project are: to assess the heart patients' and family members' needs for rehabilitation in the health system to assess the need for coordination of the rehabilitation effort in the health system to develop tele-rehabilitation concepts and technologies for heart patients, family members and health professionals in the health sector to promote an early, rapid and effective rehabilitation of heart patients to improve their daily life and working life. to prevent re-hospitalization of heart patients through a more individualized and differentiated rehabilitation effort using tele-rehabilitation technologies. to conduct a randomized study of a tele-rehabilitation concept using tele-rehabilitation technologies and to assess the clinical, technical, organizational and health-economic effects.

Eligibility criteria:
inclusion criteria: * women and men above 18 years * must have signed the "informed consent" document * must be able to understand study information * must live in hjørring or frederikshavn kommune * must have mobile network * must be able to use it or have a near person who can use it * patients with clinical diagnosis of heart failure, myocardial infarction, angina pectoris, patients who have had coronary-artery bypass surgery. exclusion criteria: * patients who, according to investigator, will not be able to participate in the study * lack of ability to speak and understand danish * pregnancy or nursing * neurologic disease * use of wheelchair/lack of ability to walk * participation in other studies which can influence the outcomes of this study

Keywords: rehabilitation telemedicine heart patients social media organisational aspects
stepped care for youth at risk of psychosis

Conditions: Clinical High Risk for Developing Psychosis

Summary: the study will recruit 60 young people who meet established criteria for being at clinical high risk for psychosis. they will be offered a range of psychological interventions starting with the most benign treatments in different steps. at step 1 they will be offered individual or group support and if there is no improvement they will be offered more intensive cbt individual therapy or cbsst group therapy. assessments will occur at baseline, 6,12 and 18 months

in treating youth at clinical high risk of developing psychosis we have not been able to address what treatment to offer first and when to offer more intense and, ultimately, more costly treatments. the goals of achieving precision health objectives require that these questions be addressed through research. the overall aim is to determine the most effective and efficient way to offer active and maintenance treatment resources for chr youth. the first step would be to offer a range of treatments starting with the most benign as advocated in the mcgorry and hickie stage model. we will use this project to test whether clinical staging will improve prediction of prognosis and result in improved matching of treatment. the specific objectives of this project are: (1) to determine which and what proportion of participants would remit (i) within the first 1-2 months of treatment, (ii) after a brief supportive therapy, (iii) after longer term, focused psychological interventions such as cbt, cbsst and family intervention and (iv) how many make use of medications; (2) to determine adherence of chr individuals to different treatments; and (3) to determine the need for maintenance treatment. to assess these objectives the following outcomes will be determined: 1. improvement of attenuated psychotic symptoms 2. improved social functioning as rated by global: social functioning 3. percentage of the sample that demonstrate either symptomatic or functional improvement after step 1 treatments and do not require to move to step 2 treatments. 4. percentage of sample that move to step 2 treatments and the percentage that achieve improvement in either symptoms or functioning. 5. percentage of participants allocated to a given treatment that adhere to the treatment. participants will be between ages 12 and 30. we will recruit 60 participants who meet well-established criteria for clinical high risk for psychosis based on the structured interview for psychosis-risk syndromes (sips). assessments will be conducted at baseline and 2, 6, 12, and 18 months after baseline. assessments consist of clinical assessments. clinical raters will be experienced raters and will be trained on all clinical measures and routine reliability checks will be conducted.

Eligibility criteria:
inclusion criteria: * meeting sips criteria for clinical high risk for psychosis exclusion criteria: * meeting criteria for any current or past axis i psychotic disorder, iq less than 70, or past or current history of a clinically significant central nervous system disorder.
positive airway pressure program

Conditions: Sleep Apnea, Obstructive

Summary: obstructive sleep apnea (osa) is a common sleep disordered breathing condition effecting around 2-4% of the middle aged population and is characterized by periodic collapse of the upper airway during sleep. continuous positive airway pressure (cpap) is the primary treatment for patients with osa. despite the effectiveness of cpap in abolishing upper airway obstruction, acceptance of and adherence with therapy has been sub-optimal. over the past decade, considerable research has focused on determining the factors responsible for poor cpap adherence. two key areas have been identified: patient-reported symptoms, including mask discomfort, pressure intolerance and nasal symptoms and the importance of patient education and support. in addition we know that the patient experience during the crucial first days and weeks of their journey predicts longer term adherence. this study investigates the ability of an automated program that assists patients towards continuous positive airway pressure (cpap) therapy adherence.


Eligibility criteria:
inclusion criteria: * ≥ 18years of age * diagnosed with osa (ahi \>5 events/hour) and eligible for cpap (fixed or auto) treatment under local requirements * naïve to cpap therapy, i.e. have not been prescribed cpap in the past 5 years * own a mobile phone, and has reliable mobile network coverage at their home. * either: the participant will use a modem; or the participant has access to a home internet connection (either their own, or a neighbours or friend etc) and is willing to perform a home upload. exclusion criteria: * contraindicated for cpap therapy * medically unstable condition/diagnosis that is not yet under control * co-existing sleep disorder (however clinically diagnosed insomnia can be included in the study) * periodic limb movement arousal index (plma) greater than 15/hr during the diagnostic study

Keywords: continuous positive airway pressure
a phase iii study of eszopiclone in patients with insomnia (study sep 190-150)

Conditions: Insomnia

Summary: the purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.

this is a multicenter, randomized, double-blinded study to evaluate the long-term safety of sep-190 (2, 3 mg) in non-elderly patients with insomnia and sep-190 (1, 2 mg) in elderly patients with insomnia.

Eligibility criteria:
inclusion criteria: 1. participants who submit written informed consent for study entry. 2. participants aged greater than or equal to 20 and less than 85 years of age at the time of obtaining informed consent. 3. participants diagnosed with primary insomnia based on the diagnostic and statistical manual of mental disorders, text revision (dsm-iv-tr) japanese version or diagnosed with insomnia associated with psychiatric or physical disorder(s). 4. participants with both of the following conditions which are persistent for 4 weeks or longer before the start of observation period: * total sleep time is less than or equal to 390 minutes for more than or equal to 3 days a week * time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week 5. participants with data at least 2 consecutive days in diary entries during observation period and confirmed to meet the following two criteria: * total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week * time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week exclusion criteria: 1. participants with a present or history of the following disease specified in mini-international neuropsychiatric interview (m.i.n.i.) japanese version 5.0: * risk of suicide * (mild) manic episode * post-traumatic stress disorder (ptsd) * alcohol dependence and abuse * drug (non-alcohol) dependence and abuse * anorexia nervosa * bulimia nervosa * anti-social personality disorder 2. participants with pharmacologically induced insomnia (drug-induced insomnia). 3. participants with comorbid primary sleep disorders (circadian rhythm disorder, restless legs movement syndrome, periodic limb movement disorder, sleep apnea syndrome, etc.) other than primary insomnia. 4. participants with symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturation, and cough. 5. participants with unstable primary disease presenting insomnia during 4 weeks before the start of observation period. 6. participants with organic mental disorder.

Keywords: insomnia primary insomnia insomnia associated with psychiatric or physical disorder(s)
evaluation of efficacy and safety of intradiscal gelified ethanol in refractory cervical discogenic pain

Conditions: Pain, Cervical; Discogenic Pain

Summary: the purpose of this study is to assesse safety and efficacy of the intradiscal gelified ethanol for treatment in refractory cervical discogenic pain.

after being informed about the study and potential tisks, all patients giving written informed consent will undergo a inclusion visit (ct scan and x ray at least) for study entry. at day 0, operation with intradiscal gelified ethanol will be performed by the investigator. follow visit will be performed at 3 months and 12 months

Eligibility criteria:
inclusion criteria: * patient 18 years or older; * pain refractory to conservative treatments for more than 2 months, non-surgical patients * cervicobrachialgia due to disc herniation * chronic discogenic pain (1 or 2 cervical discs) with concordant mri; * patient agreeing to participate in the study and having given written consent; * patient enrolled in a health insurance plan. exclusion criteria: * prior surgical treatment of the disc(s) studied; * sick leave of more than 12 months secondary to painful symptoms; * patient with modic 1 score or more * history of cognitive-behavioral disorders that could affect the completion of self-questionnaires; * local or systemic infection, or suspicion of infection; * severe coagulation disorders; * other inflammatory rheumatic disease; * severe underlying pathology with life expectancy \<1 year; * women of childbearing age who are pregnant at the inclusion visit or who wish to become pregnant before the administration of the treatment (v0); * known allergy to contrast material and/or local anesthetic substances; * patients who cannot read or write italian; * major person benefiting from a legal protection regime (guardianship, curatorship, safeguard of justice);
the influence of lidocaine volume on discomfort during administration of local anesthetic

Conditions: Needlestick Injuries

Summary: the aim of the study is to find a simple method for pain reduction that can be used in clinical practice when administering digital nerve block with a single subcutaneous injection. it will be investigated whether a smaller volume of lidocaine can decrease pain during injection.

healthy volunteers will receive a single subcutaneous injection digital nerve block at the base of each ring finger. 2ml 1% lidocaine in one of the fingers, and 1 ml 2% lidocaine in the other. after each injection, the subject will be asked to evaluate the pain on a visual analog scale (0-100 mm). additionally the sensibility will be tested with a semmes-weinstein monofilament, to evaluate if the different methods achieve desired anesthetic effect.

Eligibility criteria:
inclusion criteria: * age 18 - 65 exclusion criteria: * regular use of analgesics * known hypersensitivity of local anaesthetic * renal-, heart- or liver disease * known peripheral neuropathy or diabetes mellitus * local infection on injection site * circulation disorders in upper extremities (e.g. raynaud´s phenomenon)

Keywords: injections lidocaine pain healthy volunteers
effect of mat pilates training on women after menopause

Conditions: Physical Activity; Blood Pressure

Summary: this project aims to verify the chronic effect of mat pilates exercise on climacteric symptoms, ambulatory blood pressure responses, lipid and glucose profile and pro and anti-inflammatory and antioxidant markers in postmenopausal normotensive and hypertensive women. all volunteers received the same intervention.

the pilates program was performed three times a week for 12 weeks. initially a familiarization was made regarding the principles of the method. all volunteers underwent 24-hour blood pressure assessment using ambulatory blood pressure measurement (abpm) and venous blood samples were collected from fasting, saliva and questionnaires before and after the pilates training period.

Eligibility criteria:
inclusion criteria: * women between the ages of 40 and 70; * be post menopausal (amenorrhea for at least 12 months); * medical release to perform physical activities. * do not present physical problems or cardiovascular complications that prevent the performance of physical exercises; exclusion criteria: * to present a history of stroke or acute myocardial infarction; * smoking; * diagnosis of diabetes mellitus. * present renal pathologies. * use medications that interfere with lipid metabolism; * use of antihypertensive drugs (except for the hypertensive group); * use hormone replacement therapies; * present gastrointestinal conditions.

Keywords: pilates blood pressure postmenopausal women
obstructive sleep apnea syndrome in glaucoma

Conditions: Obstructive Sleep Apnea Syndrome; Glaucoma

Summary: the aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with osas and if the level of plasma matrix-metalloproteinase activity will decrease after one month of ncpap-treatment.

glaucoma is a leading cause of blindness world-wide. chronic primary open-angle glaucoma is the most common form among caucasian patients. the key feature of glaucoma is damage to the optic nerve head, which is not necessarily related to an increased intraocular pressure. the prevalence of glaucoma among the patients with sleep apnoea was 7,2%: normal-tension glaucoma 2,9%, primary open-angle glaucoma 4,3%. the prevalence of obstructive sleep apnoea syndrome (osas) is around 4-10% for men and 2-4% for women. matrix metalloproteinases (mmps) substrates include essentially all extracellular matrix components as well as a wide array of molecules involved in intracellular adhesion, cell-matrix interaction, and cell signalling. however, mmps effects are not restricted to extracellular matrix degradation. the prevalence of increased mmp in patients with osas and its predicting value for an additional glaucoma are not known. further, we do not know if treatment of osas with nasal continuous positive air pressure(ncpap) can decrease the mmp activity. with this study, we want to determine the prevalence of mmp activity and the prevalence of glaucoma in patients with osas. further, we want to investigate if a ncpap treatment period of four weeks decreases the mmp activity.

Eligibility criteria:
inclusion criteria: * osas planned begin of a ncpap treatment exclusion criteria: * current malignancy * oral steroids

Keywords: osas glaucoma mmp